RxSight walked into this quarter with a stock that had been roughly flat over the past week and modestly higher over the past month. The immediate reaction told a different story. The share price slipped about 3% to US$6.08 after the Q2 release, as investors focused on pressure in the income statement rather than the long runway often associated with its light adjustable lens technology.

The headline from these earnings is margin and loss pressure. Revenue for Q2 came in at US$33.7m while the company booked a net loss of US$12.1m, or US$0.29 per share. That loss, alongside softer product trends, is what investors are reacting to now.

Is RxSight now priced like a bargain on growth concerns, or is the market still paying a premium for an unclear profit path? Compare RXST’s P/S, loss profile and revenue outlook inside the valuation analysis for RxSight.

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs Q2 2025): US$33.7m vs US$33.6m (broadly flat year on year)
• Net Loss (Q2 2026 vs Q2 2025): US$12.1m loss vs US$11.8m loss (loss widened slightly)
• Basic EPS (Q2 2026 vs Q2 2025): US$0.29 loss per share vs US$0.29 loss per share (little change year on year)
• Gross Margin (Q2 2026 vs Q2 2025): 76.7% overall, with product gross margin of about 71.2% vs 74.9% (product margin compressed)

Prefer clean charts instead of scrolling through another dense earnings release? See RxSight’s full financial picture, with a clear view of its valuation trends and context, in the company report for RxSight.

RxSight Bull Case Stalls On Utilization Milestones

The bullish story around RxSight centers on the Light Adjustable Lens driving structurally higher margins and operating leverage as procedure volumes scale. This quarter shows that the key utilization milestones are not yet being met. LAL unit volume fell 9% year on year to 24,917 and product revenue excluding the Alcon collaboration declined 19%. That runs directly against the idea of growing procedure throughput across the installed base of 1,166 Light Delivery Devices.

Supporters also pointed to high 70s gross margin as proof that scale would lift profitability. Gross margin of 76.7% and product gross margin around 71.2% instead reflect pressure from inventory costs and weaker flow through. The Alcon partnership and expected US$30m to US$40m of collaboration revenue show external validation of the technology, but with full year guidance withdrawn and GAAP net loss at US$12.1m, the margin expansion leg of the bull case remains unproven.

Compare how RxSight’s internal utilization targets stack up against Wall Street expectations and whether the recent 3.3% share price drop is reflected in analyst targets. See the consensus price target analysis for RxSight

RxSight Bear Case Finds Fresh Support In Q2 Misses

The core worry around RxSight is that premium cataract focus and a heavy cost base will not translate into enough procedure volume to support the current business model. This quarter largely backs that concern. LAL unit volume fell 9% to 24,917 and product revenue excluding Alcon collaboration declined 19%, even with an installed base of 1,166 LDDs and over 2,000 surgeons trained. That directly undercuts the idea that utilization would ramp through 2026.

Bears also warned that operating expenses could outrun growth and keep losses high. SG&A rose to US$30.4m while adjusted net loss still came in at US$4.6m and GAAP net loss at US$12.1m. The decision to withdraw full year guidance, alongside margin compression to about 71.2% product gross margin, reinforces concerns about visibility and execution rather than easing them.

After recurring utilization shortfalls and continuing losses, are these just surface issues or early signs of structural strain? Review the risk analysis for RxSight which shows 2 important warning signs

Take Control Of Your Next Move

If RxSight has your attention after this quarter's margin pressure and guidance withdrawal, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the story develops. When you decide to take a position, keep a clear view of your exposure and key alerts through the Portfolio Command Center so you see the signal, not the noise. For a broader context around RxSight, compare your thesis with other investors inside the Community and see what the crowd is watching. This approach can help you identify potential catalysts or red flags early and stay prepared for changing market conditions.

Seeking Alternatives Beyond RxSight?

Markets move fast and the most interesting stocks often gain momentum before the story is widely known. Scan fresh ideas under the radar for now and get in early.

• Spot under-followed compounders early and review the curated 19 high quality undiscovered gems before they attract broader attention and the ideal entry window starts dropping out of reach.
• Target resilient cash generators and scan the hand picked list of solid balance sheet and fundamentals stocks (49 results) while valuations still reflect today’s conditions and not tomorrow’s potential breakout momentum.
• Ride structural themes with guardrails and check the focused 77 resilient stocks with low risk scores before market enthusiasm sends the most stable opportunities flying beyond your comfort zone.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.